Lipid X (2,3-diacylglucosamine 1-phosphate) is a novel
monosaccharide precursor of
lipid A (the active moiety of gram-negative
endotoxin) and has been found to be protective against
endotoxin administered to mice and sheep and against life-threatening gram-negative
infections in mice. Because of the need to design optimal dosing regimens in experimental models of ovine and murine
septicemia, the pharmacokinetic profile of
lipid X was investigated in sheep and in two strains of mice by using 32P-labeled
lipid X. In sheep, peak whole blood
lipid X levels after a bolus injection of 100 micrograms of
lipid X per kg were 900 ng/ml. An initial rapid distribution phase of 7.98 +/- 0.1 min was observed, followed by a prolonged elimination phase of 3.0 +/- 0.5 h; the area under the curve from time zero to infinity was 428 +/- 27 ng.h/ml. The serum half-lives of
lipid X were slightly shorter than whole blood half-lives, suggesting that
lipid X associates with cellular elements. Metabolites of
lipid X could not be detected in serum over a 4-h period.
Lipid X appears to accumulate mainly in the liver, and the tissue distribution of
lipid X resembles that of
lipopolysaccharide. The elimination rate of
lipid X in mice was approximately four times as rapid as that seen in sheep.
Lipid X pharmacokinetics in
lipopolysaccharide-sensitive DBA/2J mice were virtually identical with those seen in
endotoxin-resistant C3H/HeJ mice. The pharmacokinetics described here should greatly aid in the design and interpretation of animal studies investigating the therapeutic applications of
lipid X in gram-negative
septicemia.